Study guide
4.2 Patient Factors: Adherence, Efficacy & Safety
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
4.2 Patient Factors: Adherence, Efficacy & Safety
Key Takeaways Explain This Topic AI
Adherence is shaped by beliefs, health literacy, cost, regimen burden, and cognitive/physical barriers — not willpower alone.
Distinguish intentional non-adherence (beliefs, side-effect avoidance, cost) from unintentional (forgetting, complex packaging, access).
Tools such as dose administration aids, reminders, regimen simplification, and device training must match the barrier type.
Safety monitoring includes falls, confusion, hypoglycaemia, bleeding, and other patient-priority harms linked to medicines.
Efficacy should be judged against goals the patient values (symptoms, function, targets agreed with the care team), with follow-up planned.
Last updated: August 2026
4.2 Patient Factors: Adherence, Efficacy & Safety
Quick Answer: Medicines only work if patients can obtain, understand, take, and tolerate them. Assess beliefs, literacy, cost, polypharmacy burden, and physical/cognitive barriers; separate intentional from unintentional non-adherence; then match supports (simplification, dose administration aids, reminders, device training) and monitor safety and goals that matter to the patient.
Patient-centred medication management under Standard 3.1 is not only about choosing the right molecule. It is about whether the plan will work in this person’s life .
Why “non-compliance” language fails
Older training language blamed patients for “not complying.” Contemporary practice treats adherence as a shared outcome of medicine design, counselling quality, social determinants, and health system access. Intern Written scenarios often hide the real barrier behind a vague “not taking tablets regularly.” Your job is to find which barrier.
Beliefs and illness perceptions
Health beliefs strongly predict intentional non-adherence:
- “I feel fine, so I don’t need blood pressure tablets.”
- “Antibiotics didn’t work last time, so I’ll stop early this time.”
- “Natural products are safer than chemicals.”
- “My relative had a bad reaction to that drug, so I won’t start.”
- “Steroid inhalers are dangerous if used every day.” (common asthma misconception)
Counselling implication: Elicit beliefs before correcting them. Ask: “What concerns do you have about this medicine?” and “What do you already know about why it was prescribed?” Motivational, non-judgemental dialogue outperforms lectures.
Link benefit to the patient’s values: stroke prevention for a grandparent who wants to remain independent; fewer night symptoms for a parent who needs sleep; staying at work for someone with financial pressure.
Health literacy
Health literacy is the ability to obtain, understand, and use health information. Low literacy is common and not visible from appearance or English fluency alone.
Clues:
- Incomplete forms, “forgot glasses,” reverse prescription directions
- Inability to explain what a medicine is for after counselling
- Confusion between look-alike packs or similar brand names
- Nodding without teach-back success
Practical supports:
- Plain language, short sentences, one message at a time
- Teach-back: “Just to be sure I explained it clearly, how will you take this?”
Demonstrate devices; avoid jargon (say “water tablet” and the medicine name if that helps, then standardise to the label name)
- Written plans with large font; pictograms where appropriate
- Involve a carer with consent when capacity or literacy limits safe use
Never equate limited English with limited intelligence; use qualified interpreters when needed (see 4.4).
Cost and access barriers
Even with PBS subsidies, cost remains a barrier: multiple co-payments, non-PBS items, devices, and travel to pharmacy or clinic. Patients may ration medicines (e.g. take “every other day”), share medicines, or delay initiation.
Assessment questions:
- “Do you ever skip doses because of cost?”
- “Which medicines would you stop first if money were tight?” (reveals priorities and risk)
Pharmacist responses within scope:
Check PBS eligibility, Safety Net thresholds, and whether a more affordable equivalent or formulary option exists via prescriber discussion
- Prefer combination products or longer supply intervals when clinically appropriate and lawful
- Avoid starting expensive non-essential complementary products that compete with essential therapy budgets
Flag social-work or GP support for broader hardship — do not invent benefits, but do not ignore cost as a clinical problem
Polypharmacy burden
Polypharmacy increases non-adherence, interactions, and ADRs. Burden is not only tablet count — it includes timing complexity (with/without food, multiple times daily), monitoring requirements, and cognitive load.
- Burden driver Example impact Mitigation direction
- High pill count Missed doses, fatigue with regimen Deprescribe low-value drugs; combinations if safe
- Multiple daily dosing Midday doses forgotten at work Prefer once-daily options when equivalent
- Special instructions “Empty stomach,” separate from calcium Simplify timing map; written chart
- Many prescribers Duplication, conflicting advice Medication review / My Health Record reconciliation
- Device + oral mix Inhaler technique neglect Prioritise device training separately
A patient-centred plan sometimes improves outcomes by removing medicines more than by adding adherence tools to a chaotic regimen.
Cognitive and physical barriers
Cognitive: dementia, delirium, depression, intellectual disability, substance intoxication. Patients may not remember counselling, may double-dose, or may be vulnerable to exploitation.
Physical: vision impairment, arthritis limiting bottle opening or inhaler actuation, dysphagia, tremor, limited reach for topical sites.
Responses:
- Easy-open containers only when child safety is not required, or transfer strategies with carers
- Large-print labels, multi-compartment aids (see tools below)
- Liquid or dispersible forms if appropriate and stable
- Spacer devices, breath-actuated inhalers, or carer-administered options after clinical review
- Home medicines review / residential care processes where eligible and indicated
Capacity and consent rules still apply — supporting adherence never means covert dosing without legal and ethical authority.
Intentional vs unintentional non-adherence
This distinction drives the intervention.
Type Typical drivers Poor match intervention Better match intervention
Unintentional Forgetting, complex regimen, vision, packaging, disruption of routine Motivational lecture alone Reminders, dose administration aids, simplify schedule, link to habits
Intentional Beliefs, fear of ADRs, cost, perceived lack of benefit, stigma Only a blister pack Address concerns, shared decisions, side-effect management, cost solutions, negotiated goals
Mixed Both present Single tool for all Combined approach
Exam tip: If a scenario shows a patient who stopped a statin because of “muscle aches” fear after reading online, a dose administration aid alone is the wrong primary answer. If a patient with good insight forgets midday doses at work, regimen redesign beats another pamphlet on cardiovascular risk.
Tools that support adherence
Match tool to barrier:
Regimen simplification — fewest daily dosing times; align medicines to morning routine when possible; stop unnecessary “as well as” products.
Dose administration aids (DAAs / blister packs) — useful for multi-dose complexity and carer oversight; limitations include mid-cycle changes, stability of some medicines outside original packs, and false reassurance if intentional non-adherence persists.
Reminders — phone alarms, apps, SMS, dosette with visual cues, pairing with meals/teeth brushing.
Education & written action plans — asthma/COPD plans, sick-day plans for diabetes medicines where appropriate, antibiotic duration calendars.
Device training — inhalers, insulin pens, epinephrine autoinjectors; recheck technique regularly; poor technique looks like “drug failure.”
Follow-up — short call-backs after new high-risk starts; review residual tablets as a non-judgemental adherence signal.
Caution with DAAs: Some medicines are unsuitable for repacking (e.g. certain hygroscopic, light-sensitive, or original-pack-required products — check product and professional guidance). Always reconcile the pack contents when prescriptions change.
Safety as a patient factor
Adherence to an unsafe regimen is not success. Patient-centred safety screening includes:
Falls risk: sedatives, anticholinergics, antihypertensives causing postural drop, opioids, alcohol co-use
Confusion / delirium risk: anticholinergics, high-dose opioids, benzodiazepines, corticosteroid neuropsychiatric effects
- Hypoglycaemia: insulin, sulfonylureas — especially in elderly or irregular eaters
- Bleeding: anticoagulants, antiplatelets, NSAID combinations
- Sedation & driving: counsel on impairment and legal responsibilities
- Anticholinergic burden: constipation, urinary retention, dry mouth, cognitive worsening
Ask about near-misses: “Have you felt dizzy standing up?” “Any night-time wandering or new confusion?” “Any black stools or unusual bruising?”
Efficacy monitoring with patient goals
Efficacy is not only a lab number. Define success with the patient:
- Therapy area Patient-centred efficacy signals Typical objective markers (when used)
- Analgesia Function, sleep, return to activity Pain scores as adjunct only
- Antihypertensives Avoidance of symptoms of overtreatment; adherence comfort Home/clinic BP
- Diabetes Energy, hypos avoided, daily life fit HbA1c, SMBG patterns
- Antidepressants Sleep, interest, side-effect tolerability Validated symptom scales in clinic
- Inhaled therapy Night waking, reliever use, exercise tolerance Peak flow/spirometry as arranged
- Antibiotics Symptom trajectory within expected window Cultures when indicated
When efficacy seems lacking, reverse-engineer: wrong drug/dose, non-adherence, poor device technique, interacting medicines, wrong diagnosis, unrealistic timeframe (e.g. expecting full antidepressant effect in three days).
Plan review points at initiation: what improvement is expected and when; what side effects should prompt contact; what constitutes failure needing prescriber review.
Shared decision-making in practice
A patient may accept a slightly less “guideline-perfect” regimen that they will actually take over a theoretically superior plan they will abandon. Document trade-offs when advising prescribers: “Patient unable to manage thrice-daily dosing; once-daily option preferred if clinically acceptable.”
Mini-cases for exam reasoning
Case 1 — Intentional: Woman of reproductive age stops isotretinoin-related counselling partner medicine because she “isn’t sexually active this month.” Address pregnancy prevention requirements and legal/PBS program obligations with clear, respectful education — not a blister pack.
Case 2 — Unintentional: Older man on five evening medicines including a diuretic wakes nocturic and skips evening doses. Timing review (diuretic earlier) may restore adherence better than admonishment.
Case 3 — Safety vs adherence: Patient perfectly adherent to amitriptyline for neuropathic pain now has recurrent falls. Efficacy for pain does not justify ignoring falls — review anticholinergic/sedative burden and alternatives with the prescriber.
Patient factors turn a correct pharmacological choice into a workable, monitored care plan — the essence of Standard 3.1.